Banach, M and Penson, P (2021) Colchicine and Cardiovascular Outcomes: A Critical Appraisal of Recent Studies. Current Atherosclerosis Reports, 23. ISSN 1523-3804

Preview

Text Banach-Penson2021_Article_ColchicineAndCardiovascularOut.pdf - Published Version Available under License Creative Commons Attribution. Download (295kB) | Preview

Abstract

Purpose of review: Recent studies have demonstrated an important role for inflammation in the pathogenesis of atherosclerotic cardiovascular disease. Several studies have investigated the efficacy of colchicine (a widely used and safe anti-inflammatory drug) in patients with atherosclerosis. This review explains the rationale for the use of colchicine in this setting, and critically appraises recent outcomes trials.
Recent findings: Two large randomised-controlled trials LoDoCo2 (included patients with chronic coronary syndromes) and COLCOT (acute coronary syndromes) have demonstrated reductions in atherosclerotic cardiovascular events, but not mortality. A smaller study (COPS) found no beneficial effect of colchicine but was probably underpowered.
Summary: Colchicine is effective at reducing cardiovascular events in chronic and acute coronary syndromes, although reductions in all-cause mortality have not been demonstrated during the period of follow up in trials to date. Mild gastrointestinal symptoms are the most commonly reported adverse effects, although in well-designed randomised controlled trials these are relatively uncommon.

Item Type:	Article
Uncontrolled Keywords:	1102 Cardiorespiratory Medicine and Haematology
Subjects:	R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology
Divisions:	Pharmacy & Biomolecular Sciences
Publisher:	Springer
Date Deposited:	01 Mar 2021 09:57
Last Modified:	07 Jan 2022 15:15
DOI or ID number:	10.1007/s11883-021-00932-5
URI:	https://researchonline.ljmu.ac.uk/id/eprint/14526

View Item